p33~(ING1b)在急性白血病中的表达及意义
摘要
背景与目的
急性白血病(Acute Leukemia, AL),已被认为是严重威胁人类身体健康的恶性肿瘤之一。该疾病的特征为原始和(或)幼稚细胞增殖发生异常,同时分化、凋亡也会受到不同程度抑制。AL的发病机制目前尚未十分明确,但有研究显示它的发生发展与原癌基因的活化、抑癌基因的灭活有关。
抑癌基因是启动细胞癌变的主要因素,对细胞生长起负调控作用,基因缺失、突变或错位等诸多因素均可引起抑癌基因功能异常。生长抑制因子-1(Inhibitorof growthl,ING1)是新近发现的一种抑癌基因,在几乎所有的正常细胞中较广泛表达。ING1基因通过不同的转录剪切方式翻译出不同分子量的蛋白质,p33INGlb是ING1编码的重要蛋白质,在肿瘤的发生发展中起着非常重要的作用,其磷酸化状态决定它参与细胞周期调控等多种生物学功能。在正常组织细胞中,p33INGlb蛋白在GO进入G1期时表达量减少,在G1晚期又出现增加趋势,在S期达到最大值,接着在G2期表达水平降低。
有研究表明,ING1基因核表达减少的现象在一部分良性肿瘤以及几乎所有恶性肿瘤的组织细胞中均可出现。目前p33INGlb在急性白血病患者中的表达及其可能参与的发病机制已有报道,但是应用逆转录聚合酶链反应(reverse transcriptase-polymerase chain reaction)RT-PCR法检测不同类型急性白血病患者p33INGlb的表达情况以及其与AL骨髓外浸润及复发的相关报道较少。本实验通过RT-PCR法检测p33ING1b在不同类型和不同疾病阶段急性白血病患者的骨髓单个核细胞中表达情况及表达水平的差异,分析p33INGlb与AL患者临床表现的相关性,进而探讨其在AL发生发展中可能参与的作用机制。
材料与方法
1研究对象
65例病例来自2010年12月-2012年3月我院住院或门诊急性白血病患者,平均年龄34(15-68)岁。(1)初治组46例；男性20例,女性26例,其中急性髓系白血病(AML)32例(AML-M219例,AML-M37例,AML-M52例),急性淋巴细胞白血病(ALL)14例；(2)完全缓解组12例；AML8例,ALL4例；(3)复发组7例；男3例,女4例；(4)正常对照组；为8名骨髓象正常的非恶性血液病患者。
2实验方法
RT-PCR法检测p33ING1bmRNA的表达水平：取骨髓标本,分离单个核细胞后Trizol法提取实验细胞总RNA并检测其质量及浓度,逆转录成cDNA, PCR扩增,琼脂糖凝胶电泳后,将琼脂糖凝胶放入凝胶成像扫描仪中紫外线下成像,用凝胶图像分析系统观察、分析实验结果并拍照。
3统计分析
实验结果应用SPSS17.0统计学软件分析,对定量资料使用平均值±标准差即x±sd,采用t检验对两样本均数进行比较,应用方差分析对多样本均数比较,定性资料采用卡方检验及Fisher's精确概率试验,采用Spearman分析相关性,以a=0.05为检验水准。
结果
1. p33ING1bmRNA在AL初治组、复发组、缓解组中的阳性率分别为45.7%(21/46),42.9%(3/7),58.3%(7/12), p33ING1bmRNA的表达水平分别为0.203±0.106,0.389±0.027,0.627±0.202；正常对照组的阳性率为87.5%(7/8),它们的阳性细胞率及表达水平明显低于对照组。复发组的阳性率及表达水平与缓解组比较,差异具有统计学意义(p<0.05)；复发组与初治组的阳性率差异无统计学意义(p>0.05),但表达水平差异有统计学意义(p<0.05)；初治组的表达水平及阳性率分别为0.203-0.106、45.7%与缓解组的阳性率58.3%及表达水平0.627±0.202比较差异有统计学意义(p<0.05)
2. AML患者p33ING1b的阳性表达率为45.5%(20/44)而ALL为52.38%(11/21),两组平均表达水平分别为0.491±0.173、0.565±0.221,阳性表达率及平均表达水平差异无统计学意义(p>0.05)。
3.p33ING1bmRNA的表达水平与AL的骨髓外浸润、患者的性别、年龄无明显相关性(p>0.05)
结论
1.p33ING1bmRNA在急性白血病中低表达,在缓解组的表达水平较初治组和复发组高,差异有统计学意义,提示p33ING1b的低表达可能与急性白血病的发生发展有关。
2.p33ING1bmRNA在初治ALL和AML患者中均低表达,差异无统计学意义,提示其低表达与白血病的类型可能无关。
3.p33ING1bmRNA的表达水平与急性白血病患者的性别、年龄、髓外浸润等临床特征无相关性。
Background and Purpose
Acute Leukemia (Acute Leukemia, AL), it is a serious threat to human health of cancer for it's increased high morbidity and mortality. The characteristics of AL is the original or childish abnormal cell proliferation, differentiation and apoptosis is inhabited. The pathogenesis of AL is not clear, but research shows that it has contact with protocarcinogenic gene activation and the inactivation of tumor-suppressor gene. Tumor-suppressor gene is a important change factor that leads to cell abnormal.This abnormal function of cells is caused by many reasons such as gene loss, mutation, displacement and so on.It play a negative role in cell growth. Tumor suppressor gene is an initiation factor for malignant cells,which caused by many reasons causing dysfunction such as gene deletion, mutation, dislocation, and has the negative regulation of cell growth. Growth inhibitory factor-1(Inhibitor of growthl, ING1) is a recently discovered tumor suppressor gene, widely expressed in normal human tissues and a variety of tumor tissue, and related to cell cycle regulation, through different transcription cut way to translate the different molecular proteins, P33ING1b is the main product of its transcription and translation as well as important tumor suppressor gene. The phenomenon of its nuclear expression decreased and cytoplasmic over-expression may occur in some benign and almost all malignant tissue cells. ING1gene translate a molecular weight of alien protein by different shear mode and p33ING1b is the protein encoded by ING1,involved in a variety of biological function mechanism such as cell cycle regulation depends on its phosphorylation state, playing a very important role in tumor development. In normal tissue cells, p33ING1b protein reduced from GO to G1phase, increased in the G1late phase and reached its maximum in the S phase, and then lower in the G2phase.In recent years, related studies have shown that P33INGlb protein expressed in the nucleus of bone marrow mononuclear cells in normal human and acute leukemia patient. The possible mechanisms of p33ING1b in the pathogenesis of acute leukemia have been reported, but the detection of p33ING1b by PCR in acute leukemia patients has not been reported in the domestic. This issue through real-time quantitative PCR to found the difference of the INGlb gene expression level between normal human and AL patients with different stages, analysing the relatation between p33ING1b and the clinical relevance of AL patients and exploring its possible mechanism in the AL.
Methods
1. An object of study:65cases from our hospital or clinic patients with acute leukemia from December2010to March,2012, the average age is34(15-68) years.(1) The untreated group,46cases;20males and26females, including32cases of acute myeloid leukemia (AML)(AML-M219cases,7cases of AML-M3AML-M52cases),14cases of acute lymphoblastic leukemia (ALL);(2) complete remission group,12cases;8cases of AML,4cases of ALL;(3) The group of7cases of recurrence;3males and4females;(4) normal control group;8cases non-hematologic malignancies patients with normal bone marrow.
2. RNA extraction and reverse transcription:bone marrow samples, separate mononuclear cells,then extract experiment total cellular RNA by Trizol and detect the quality and concentration,maging under ultraviolet light, and then systematic observation, analysis the experimental results and photographed using gel image analysis.
3. Statistical analysis:Using Software SPSS17.0analyze the data. Quantitative data were expressed as mean±tandard deviation (x±SD); Paired means were analyzed by Independent-Samples t-test, while Various means were analyzed by variance analysis. Qualitative data were analyzed by chi-square test; The standard of significant level was a=0.05.
Result
1. p33ING1b in the untreated group of AL, the positive rate of45.7%(21/46), recurrent group was42.9%(3/7), the remission group was58.3%(7/12), the expression level of the P33were0.203±0.106,0.389±0.027,0.627±0.202; normal control group, the positive rate was87.5%(7/8). The positive rate of the recurrence group was significantly lower than the positive rate of the remission group and normal control group, the difference between the recurrence group and the latter two groups was statistically significant (p<0.05); the difference of the positive rate between the early treatment group and remission group had no statistically significant (p>0.05) but the difference of expression level was statistically significant (p<0.05); the differences of expression levels and the positive rate between the recurrence group and the remission group were statistically significant (p<0.05);
2. the positive expression rate was45.5%(20/44) in AML,52.38%(11/21) in ALL, the expression levels of two sets were0.491±0.173,0.495±0.221, the differences of the positive rate and expression levels had no statistically significant (p>0.05).
3. The expression level of p33ING1b mRNA has no significant correlation with the bone marrow and infiltration, patients for gender, age,(p>0.05).
Conclusion
1. p33ING1b low expressed in the AL; the expression of recurrence is lowest, the difference had statistics meaning, this may indicate lower expression of p33ING1b gene may play a role in the occurrence and development of acute leukemia.
2. p33ING1b has low expression level in the AML group and ALL group group, the difference was statistically significant, suggesting that the low-expression of p33ING1b may had no meaning to the type of acute leukemia.
3. The expression level of p33ING1b in acute leukemic patients has no relevation witn gender, age, and infiltration.
急性白血病(Acute Leukemia, AL),已被认为是严重威胁人类身体健康的恶性肿瘤之一。该疾病的特征为原始和(或)幼稚细胞增殖发生异常,同时分化、凋亡也会受到不同程度抑制。AL的发病机制目前尚未十分明确,但有研究显示它的发生发展与原癌基因的活化、抑癌基因的灭活有关。
抑癌基因是启动细胞癌变的主要因素,对细胞生长起负调控作用,基因缺失、突变或错位等诸多因素均可引起抑癌基因功能异常。生长抑制因子-1(Inhibitorof growthl,ING1)是新近发现的一种抑癌基因,在几乎所有的正常细胞中较广泛表达。ING1基因通过不同的转录剪切方式翻译出不同分子量的蛋白质,p33INGlb是ING1编码的重要蛋白质,在肿瘤的发生发展中起着非常重要的作用,其磷酸化状态决定它参与细胞周期调控等多种生物学功能。在正常组织细胞中,p33INGlb蛋白在GO进入G1期时表达量减少,在G1晚期又出现增加趋势,在S期达到最大值,接着在G2期表达水平降低。
有研究表明,ING1基因核表达减少的现象在一部分良性肿瘤以及几乎所有恶性肿瘤的组织细胞中均可出现。目前p33INGlb在急性白血病患者中的表达及其可能参与的发病机制已有报道,但是应用逆转录聚合酶链反应(reverse transcriptase-polymerase chain reaction)RT-PCR法检测不同类型急性白血病患者p33INGlb的表达情况以及其与AL骨髓外浸润及复发的相关报道较少。本实验通过RT-PCR法检测p33ING1b在不同类型和不同疾病阶段急性白血病患者的骨髓单个核细胞中表达情况及表达水平的差异,分析p33INGlb与AL患者临床表现的相关性,进而探讨其在AL发生发展中可能参与的作用机制。
材料与方法
1研究对象
65例病例来自2010年12月-2012年3月我院住院或门诊急性白血病患者,平均年龄34(15-68)岁。(1)初治组46例；男性20例,女性26例,其中急性髓系白血病(AML)32例(AML-M219例,AML-M37例,AML-M52例),急性淋巴细胞白血病(ALL)14例；(2)完全缓解组12例；AML8例,ALL4例；(3)复发组7例；男3例,女4例；(4)正常对照组；为8名骨髓象正常的非恶性血液病患者。
2实验方法
RT-PCR法检测p33ING1bmRNA的表达水平：取骨髓标本,分离单个核细胞后Trizol法提取实验细胞总RNA并检测其质量及浓度,逆转录成cDNA, PCR扩增,琼脂糖凝胶电泳后,将琼脂糖凝胶放入凝胶成像扫描仪中紫外线下成像,用凝胶图像分析系统观察、分析实验结果并拍照。
3统计分析
实验结果应用SPSS17.0统计学软件分析,对定量资料使用平均值±标准差即x±sd,采用t检验对两样本均数进行比较,应用方差分析对多样本均数比较,定性资料采用卡方检验及Fisher's精确概率试验,采用Spearman分析相关性,以a=0.05为检验水准。
结果
1. p33ING1bmRNA在AL初治组、复发组、缓解组中的阳性率分别为45.7%(21/46),42.9%(3/7),58.3%(7/12), p33ING1bmRNA的表达水平分别为0.203±0.106,0.389±0.027,0.627±0.202；正常对照组的阳性率为87.5%(7/8),它们的阳性细胞率及表达水平明显低于对照组。复发组的阳性率及表达水平与缓解组比较,差异具有统计学意义(p<0.05)；复发组与初治组的阳性率差异无统计学意义(p>0.05),但表达水平差异有统计学意义(p<0.05)；初治组的表达水平及阳性率分别为0.203-0.106、45.7%与缓解组的阳性率58.3%及表达水平0.627±0.202比较差异有统计学意义(p<0.05)
2. AML患者p33ING1b的阳性表达率为45.5%(20/44)而ALL为52.38%(11/21),两组平均表达水平分别为0.491±0.173、0.565±0.221,阳性表达率及平均表达水平差异无统计学意义(p>0.05)。
3.p33ING1bmRNA的表达水平与AL的骨髓外浸润、患者的性别、年龄无明显相关性(p>0.05)
结论
1.p33ING1bmRNA在急性白血病中低表达,在缓解组的表达水平较初治组和复发组高,差异有统计学意义,提示p33ING1b的低表达可能与急性白血病的发生发展有关。
2.p33ING1bmRNA在初治ALL和AML患者中均低表达,差异无统计学意义,提示其低表达与白血病的类型可能无关。
3.p33ING1bmRNA的表达水平与急性白血病患者的性别、年龄、髓外浸润等临床特征无相关性。
Background and Purpose
Acute Leukemia (Acute Leukemia, AL), it is a serious threat to human health of cancer for it's increased high morbidity and mortality. The characteristics of AL is the original or childish abnormal cell proliferation, differentiation and apoptosis is inhabited. The pathogenesis of AL is not clear, but research shows that it has contact with protocarcinogenic gene activation and the inactivation of tumor-suppressor gene. Tumor-suppressor gene is a important change factor that leads to cell abnormal.This abnormal function of cells is caused by many reasons such as gene loss, mutation, displacement and so on.It play a negative role in cell growth. Tumor suppressor gene is an initiation factor for malignant cells,which caused by many reasons causing dysfunction such as gene deletion, mutation, dislocation, and has the negative regulation of cell growth. Growth inhibitory factor-1(Inhibitor of growthl, ING1) is a recently discovered tumor suppressor gene, widely expressed in normal human tissues and a variety of tumor tissue, and related to cell cycle regulation, through different transcription cut way to translate the different molecular proteins, P33ING1b is the main product of its transcription and translation as well as important tumor suppressor gene. The phenomenon of its nuclear expression decreased and cytoplasmic over-expression may occur in some benign and almost all malignant tissue cells. ING1gene translate a molecular weight of alien protein by different shear mode and p33ING1b is the protein encoded by ING1,involved in a variety of biological function mechanism such as cell cycle regulation depends on its phosphorylation state, playing a very important role in tumor development. In normal tissue cells, p33ING1b protein reduced from GO to G1phase, increased in the G1late phase and reached its maximum in the S phase, and then lower in the G2phase.In recent years, related studies have shown that P33INGlb protein expressed in the nucleus of bone marrow mononuclear cells in normal human and acute leukemia patient. The possible mechanisms of p33ING1b in the pathogenesis of acute leukemia have been reported, but the detection of p33ING1b by PCR in acute leukemia patients has not been reported in the domestic. This issue through real-time quantitative PCR to found the difference of the INGlb gene expression level between normal human and AL patients with different stages, analysing the relatation between p33ING1b and the clinical relevance of AL patients and exploring its possible mechanism in the AL.
Methods
1. An object of study:65cases from our hospital or clinic patients with acute leukemia from December2010to March,2012, the average age is34(15-68) years.(1) The untreated group,46cases;20males and26females, including32cases of acute myeloid leukemia (AML)(AML-M219cases,7cases of AML-M3AML-M52cases),14cases of acute lymphoblastic leukemia (ALL);(2) complete remission group,12cases;8cases of AML,4cases of ALL;(3) The group of7cases of recurrence;3males and4females;(4) normal control group;8cases non-hematologic malignancies patients with normal bone marrow.
2. RNA extraction and reverse transcription:bone marrow samples, separate mononuclear cells,then extract experiment total cellular RNA by Trizol and detect the quality and concentration,maging under ultraviolet light, and then systematic observation, analysis the experimental results and photographed using gel image analysis.
3. Statistical analysis:Using Software SPSS17.0analyze the data. Quantitative data were expressed as mean±tandard deviation (x±SD); Paired means were analyzed by Independent-Samples t-test, while Various means were analyzed by variance analysis. Qualitative data were analyzed by chi-square test; The standard of significant level was a=0.05.
Result
1. p33ING1b in the untreated group of AL, the positive rate of45.7%(21/46), recurrent group was42.9%(3/7), the remission group was58.3%(7/12), the expression level of the P33were0.203±0.106,0.389±0.027,0.627±0.202; normal control group, the positive rate was87.5%(7/8). The positive rate of the recurrence group was significantly lower than the positive rate of the remission group and normal control group, the difference between the recurrence group and the latter two groups was statistically significant (p<0.05); the difference of the positive rate between the early treatment group and remission group had no statistically significant (p>0.05) but the difference of expression level was statistically significant (p<0.05); the differences of expression levels and the positive rate between the recurrence group and the remission group were statistically significant (p<0.05);
2. the positive expression rate was45.5%(20/44) in AML,52.38%(11/21) in ALL, the expression levels of two sets were0.491±0.173,0.495±0.221, the differences of the positive rate and expression levels had no statistically significant (p>0.05).
3. The expression level of p33ING1b mRNA has no significant correlation with the bone marrow and infiltration, patients for gender, age,(p>0.05).
Conclusion
1. p33ING1b low expressed in the AL; the expression of recurrence is lowest, the difference had statistics meaning, this may indicate lower expression of p33ING1b gene may play a role in the occurrence and development of acute leukemia.
2. p33ING1b has low expression level in the AML group and ALL group group, the difference was statistically significant, suggesting that the low-expression of p33ING1b may had no meaning to the type of acute leukemia.
3. The expression level of p33ING1b in acute leukemic patients has no relevation witn gender, age, and infiltration.
引文
[1]Soliman M A, Riabowol K. After a decade of study-ING, a PHD for a versatile family of proteins. Trends Biochem Sci.2007,32:509-519.
[2]Ythier D, Larrieu D, Brambilla C,et al. The new tumor suppressor genes ING:Genomic structure and status in cancer. Int J Cancer.2008,123:1483-1490.
[3]Coles AH,Marfella CG,Imbalzano AN,et al. p37Inglb regulates B-cell proliferation and cooperates with p53 to suppress diffuse large B-cell lymphoma genesis. Cancer Res. 2008,68:8705-8714
[4]Garkavtsev I, Kazarov A,Riabowol K,et al.Suppression of the novel growth inhibitor p33ING1 promotes neoplastictransformation. Nat Genet.1996,14 (5):415-420.
[5]Baranova AV, Ivanov DV, Makeeva NV,et al. Genomic organization of a tumor growth inhibitor gene ING1. Mol Biol.2000,34:232-236.
[6]Gunduz M, Ouchida M, Fukushima K,et al. Genomic structure of the human ING1 gene and tumor-specific mutations detected in head and neck squamous cell carcinomas. Cancer Res.2000,60:3143-3146.
[7]Garkavtsev I.Suppression of the novel growth inhibitor p33 (ING1) promotes neoplastic transformation. Nat Genet.1999,23:373-73.
[8]Jager D,Stockert E,Scanlan MJ, et al. Cancer-testis antigens and ING1 tumor suppressor gene product are breast cancer antigens:characterization of tissue-specific ING1 transcripts and a homologue gene. Cancer Res.1999,59:6197-6204.
[9]Saito A,Furukawa T, Fukushige S, et al. p24/ING1-ALT1 and p47/ING1-ALT2, distinct alternative transcripts of p3ING1. Hum Genet.2000,45:177-181.
[10]Ha S, Park S, Yun CH, Choi Y. Characterization of nuclear localization signal in mouse ING1 homolog protein. Biochemical and Biophysical Research Communications.2002, 293(1):163-166.
[11]Nouman GS,Angus B,Lunec J, et al. Comparative assessment of ex2pression of the inhibitor of growth 1 gene (ING1) in normal and neoplastic tissues. Hybridoma.2002,21 (1):1-10.
[12]Tamannai M, Farhangi S, Truss M, et al. The inhibitor of growth 1 (ING1) is involved in trichostatin A-induced apoptosis and caspase 3 signaling in p53-deficient glioblastoma cells. Oncol Res.2010,18(10):469-480.
[13]Helbing CC, Veillette C, Riabowol K, et al. A novel candidate tumor suppressor, ING1, is involved in the regulation of apoptosis. Cancer Res.1997,57:1255-1258.
[14]Turovets NA, Agapova LS, Kopnin PB, et al. Inactivation of p33(ING1) tumor suppressor affects the function of the cell cycle "checkpoints" and stability of the genome. Genetika. 2000,36:305-12.
[15]Garkavtsev I.Suppression of the novel growth inhibitor P33ING1 promotes neoplastie transformation. Nat Genet.1999,23(3):373.
[16]Dan- Hua Shen,Kelvin Yuen- Kwong Chan,Ui-Soon Khoo,etal. Epigenetic and genetic alterations of p33ING1b in ovarian cancer.J Carcinogenesis.2005,26(4):855-863.
[17]Cheung K J Jr, Li G. The tumor suppressor ING1:structure and function.J Exp Cell Res.2001,268(1):1-6.
[18]Kuzmichev,Zhang Y,Erdjument-Bromage H,et al.Role of the Sin3- histone deacetylase complex in growth regulation by the candidate tumor suppress or p33INGI. Mol Cell Biol.2002,22(3):835-848.
[19]Scott M, Bonnefin P, Vieyra D, et al.UV- induced binding of INGI to PCNA regulates the in duetion of apoptosis.J Cell Sci.2001,114(ptl9):3455-3462.
[20]Lv Y, Purbey BK, Huang Y, Li S,et al.Adenovirus-mediated expression of p33(INGlb) induces apoptosis and inhibits proliferation in gastric adenocarcinoma cells in vitro.Gastric Cancer.2012, Jan 12.
[21]Shimada H,Liu TL,Ochiai T,et al. Faeiliation of adenoviral wild-type p53-induced apoptotie cell death by ovrexpresslon of p331NGI in T.Tnhuman esophageal earcinomaces Oneogene.2002,21:1208-1216.
[22]Oki E, Maehara Y,Tokumaga E,etal. Reduced expression of p33ING1b and the relationship with p53 expression in buman gastric cancer. Cancer Lett,1999,147:157-162.
[23]Toyama T,lwase H, Watson P,et al.Suppression of INGI expression in sporadic breast cancer Oncugene.1999,18:5187-5193.
[24]Oki E, Maehara Y, Tokunage E,etal. Reduced expression of p33 INGlb and the relationship with p53 expression in human gastric cancer. Carlcer Letters.1999,147-157.
[25]G S Noumanl, J J Andersonl, K M Wood,et al. Loss of nuclear expression of the p33INGlb inhibitor of growth protein in childhood acute lymphoblastic leukaemia. J Clin Pathol 2002,55:596-601.
[26]Campos El, Chin MY, Kuo WH. Biological functions of the ING family tumor suppressors. Cell Mol Life Sci.2004,61(19-20):2597-613.
[27]Coles AH, Jones SN. The ING gene family in the regulation of cell growth and tumorigenesis. Journal of Cellular Physiology.2009,18(1):45-57.
[28]Pena PV, Davrazou F, Shi X, et al. Molecular mechanism of histone H3K4me3 recognition by plant homeodomain of ING2. Nature.2006,442(7098):100-103.
[29]Nouman GS, Anderson JJ, Lunec J. The role of the tumour suppressor p33 INGlb in human neoplasia. Clin Pathol.2003,56:491-496.
[30]Ythier D, Larrieu D, Brambilla C, Brambilla E, Pedeux R. The new tumor suppressor genes ING:genomic structure and status in cancer. Cancer.2008,123:1483-1490.
[31]Garkavtsev I,Demetrick D,Riabowol K.Cellular localization and chromosome mapping of a novel candidate tumor suppressor gene (ING1).Cytogenet Cell Genet.1997,76(3-3):176-8.
[32]Nouman GS,Angus B,Lunec J,et al. Comparative assessment of expression of the inhibitor of growth 1 gene(ING1) in normal and neoplastic tissues. Hybridoma.2002,21(1):1-10.
[33]Ludwig S, Klitzsch A, Baniahmad A.The ING tumor suppressors in cellular senescence and chromatin. Cell Biosci.2011,1(1):25.
[34]Campos E1, Cheung KJ Jr, Murray A,et al. The novel tumour suppressor gene ING1 is overexpressed in human melanoma cell lines.Br J Dermatol.2002,146(4):574-580.
[35]贺平,陈兴平.肿瘤抑制因子p33 INGlb的研究进展.实用医学杂志.2008,24(21)：3784-3785.
[36]Goeman F, Thormeyer D, Abad M,et al. Growth inhibition by the tumor suppressor p33ING1 in immortalized and primary cells:Involvement of two silencing domains and effect of Ras. Mol Cell Biol.2005,25:422-431.
[37]Kuzmichev,Zhang Y,Erdjument-Bromage H,et al.Role of the Sin3-histone deacetylase complex in growth regulation by the candidate tumor suppress or P33(INGI). Mol Cell Biol.2002,22(3):835-848.
[38]Scott M, Bonnefin P, Vieyra D, et al.UV-induced binding of INGI to PCNA regulates the in duetion of apoptosis. Cell Sci,2001,114(19):3455-3462.
[39]李伟,周鹏,胡红梅.p33INGlb蛋白的结构及其基因分子生物学Science and Technology.2008,29(8):70-71.
[40]Menendez C, Abad M, Gomez-Cabello D, Moreno A, Palmero I. ING proteins in cellular senescence. Curr Drug Targets.2009,10:406-417.
[41]Abad M, Moreno A, Palacios A, Narita M, Blanco F, Moreno-Bueno G, Narita M, Palmero I. The tumor suppressor ING1 contributes to epigenetic control of cellular senescence. Aging Cell.2011,1:158-171.
[42]Schuler M, Green DR. Mechanisms of p53-dependent apoptosis.Biochem Soc Trans. 2001,29(6):684-688.
[43]朱晋军,廖威明,李佛保等.p33INGlb增强骨肉瘤细胞U20S对足叶乙甙的敏感性.癌症,2004,23(6)：640-644.
[44]Leung KM, Po LS, Tsang FC, et al.The candidate tumor suppressor INGlb can stabilize p53 by disrupting the regulation of p53 by MDM2.Cancer Res.2002,62(17):4890-4893.
[45]Tsang FC,Po LS,Leung KM,etal.INGlb decreases cell proliferation through p53-dependent and-independent mechanislns. FEBS Lett.2003,553(3):277-285.
[46]赵帅,贺修胜,吕文玲等.p33INGlb基因对SW480细胞生长增殖的影响.中国癌症杂志.2008,18(8)：578-582.
[47]Jost CA, Marin MC, Kaelin WG, et al.p73 is a human p53-related protein that can induce apoptosis.Nature.1997,389(6647):191-194.
[48]Irwin MS,Kaelim W C,P53 family update:p73 and p63 develop their own identities. Cell Growth Differ.2001,12(7):337-349.
[49]Moll UM. Slade N. p63 and p73:roles in development and tumor formation. Mol Cancer Res.2004,2(7):371-386.
[50]Ito K, Kinjo K, Nakazato T,et al. Expression and sequence analysis of p33INGlgene in myeloid leukemia. Hematology.2002,69:141-143.
[51]Nouman GS, Anderson JJ, Crosier S,et al. Down-regulation of nuclear expression of the p33ING1b inhibitor of growth protein in invasive carcinoma of the breast.J Clin Pathol.2003 Jul;56(7):507-511.
[1]Garkavtsev I, Riabowol K. Extension of the replicative life span of human diploid fibroblast by inhibition of the p33ING1 candidate tumor suppressor.Mol Cell Boil.1997,17:2014.
[2]Zeremski m, Horrigan SK, Grigorian IA,et al.Localizaton of the candidate tumor suppressor gene ING1 to human chromosome 13q34.Somat Cell Mol Genet.1997,23(3): 233.
[3]He GH, Helbing CC, Wagner MJ, Sensen CW, Riabowol K. Phylogenetic analysis of the ING family of PHD finger proteins. Mol Biol Evol.2005;22:104-116.
[4]Ludwig S, Klitzsch A, Baniahmad A. The ING tumor suppressors in cellular senescence and chromatin. Cell Biosic.2011 Jul 18;1(1):25.
[5]Coles AH, Jones SN. The ING gene family in the regulation of cell growth and tumorigenesis. J Cell Physiol.2009;218:45-57.
[6]Li X, Kikuchi K, Takano Y. ING Genes Work as Tumor Suppressor Genes in the Carcinogenesis of Head and Neck Squamous Cell Carcinoma. J Oncol.2011;2011:963614.
[7]Garkavtsev I, Demetrick D, Riabowol K.Cellular localization and chromosome mapping of a novel candidate tumor suppressor gene (INGl).Cytogenet Cell Genet.1997,76(3-3): 176-8.
[8]Gunduz M,Ouchida M,Fukushima K,et al.Genomic structure of the human ING1 gene and tumor-specific mutations detected in head and neck squamous cell carcinomas.Cancer Res.2000,60:3143.
[9]Garkavtsev I, Kazarov A,Riabowol K,et al.Suppression of the novel growth inhibitor p331NG1 promotes neoplastic transformation. J Nat Genet.1996,14 (5)).415-420.
[10]Cheung K J Jr, Li G. The tumor suppressor ING 1:structure and function.J Exp Cell Res. 2001,268(1):1-6.
[11]Gundun M, Ouchida M, Fukushima K, et al. Genomic structure of the human ING1 gene and tumor-specific mutations detected in head and neck squamous cell carcinomas.Cancer Res.2000,60:3143.
[12]Jager cer-testisD,Stockert E,Scanlan MJ,et al.Cancer-testis antigens and ING1 tumor suppressor hene product are breast cancer antigens:characterization of tissue-specific ING1 transcripts and a homologue gene.Cancer Res.1999,59:6197
[13]Jenuwein T,Allis CD.Translating the histone code. Science.2001,293(5532):1074-1080.
[14]He GH,Helbing CC,Wagner MJ,et al. Phylogenetic analysis of the ING family of PHD finger proteins. Mol BiolEvol.2005,22(1):104-116.
[15]Pena PV, Davrazou F, Shi X, et al. Molecular mechanism of histone H3K4me3 recognition by plant homeodomain of ING2. Nature.2006,442(7098):100-103.
[16]Turovets NA,Agapova LS,Kopnin PB,et al. Effect of inactivating the p33ING1 tumor suppressor on the function of cell cycle "checkpoints" and genome stability.Genetika.2000, 36(3):385.
[17]Goeman F, Thormeyer D, Abad M, et al. Growth inhibition by the tumor suppressor p33ING1 in immortalized and primary cells:Involvement of two silencing domains and effect of Ras. Mol Cell Biol.2005,25:422-431.
[18]Schwarze SR, DePrimo SE, Grabert LM, et al. Novel pathways associated with bypassing cellular senescence in human prostate epithelial cells. J Biol Chem.2002,17:14877-14883.
[19]Wong RP, Lin H, Khosravi S,et al. Tumour suppressor INGlb maintains genomic stability upon replication stress. Nucleic Acids Res.2011,39(9):3632-3642.
[20]Skowyra D, Zeremski M, Neznanov N, et al. Differential association of products of alternative transcripts of the candidate tumor suppressor ING1 with the mSin3/HDACl transcriptional compressor complex.Journal of Biological Chemistry. 2001,276(12):8734-8739.
[21]Vieyra D, Loewith R, Scott M, et al. Human ING1 proteins differentially regulate histone acetylation. Journal of Biological Chemistry.2002,277(33):29832-29839.
[22]Kuzmichev A, Zhang Y, Erdjument-Bromage H,et al. Role of the Sin3-histone deacetylase complex in growth regulation by the candidate tumor suppressor p33ING1.Molecular and Cellular Biology.2002,22(3):835-848.
[23]Scott M, Bonnefin P, Vieyra D, et al.UV-induced binding of INGI to PCNA regulates the in duetion of apoptosis.J Cell Sci,2001,114(19):3455-3462.
[24]李伟,周鹏,胡红梅.P33ING1b蛋白的结构及其基因分子生物学Science and Technology.2008,29(8):70-71.
[25]Leung KM, Po LS, T sang FC, et al. The candidate tumor suppressor INGlb can stabilize p53 by disrupting the regulation of p53 by MDM2. Cancer Res.2002,62(17):4890-4893.
[26]Li N, Li Q, Cao X,et al. The tumor suppressor p33INGlb upregulates p16INK4a expression and induces cellular senescence.FEBS Lett.2011,585(19):3106-3112.
[27]Abad M, Moreno A, Palacios A, et al. The tumor suppressor ING1 contributes to epigenetic control of cellular senescence. Aging Cell.2011,1:158-71.
[28]Vicencio JM, Galluzzi L, Tajeddine N, et al. Senescence, apoptosis or autophagy? When a damaged cell must decide its path-a mini-review. Gerontology.2008,54(2):92-99.
[29]Campisi J, Adda d, Fagagna F. Cellular senescence:when bad things happen to good cells. Nat Rev Mol Cell Biol.2007,8:729-740.
[30]Courtois-Cox S, Jones SL,Cichowski K. Many roads lead to oncogene-induced senescence Oncogene.2008,27:2801-9.
[31]Lara MF, Paramio JM, Mol Carcinog.The Rb family connects with the Tp53 family in skin carcinogenesis.2007,46(8):618-23.
[32]Menendez C, Abad M, Gomez-Cabello D, Moreno A, Palmero I. ING proteins in cellular senescence. Curr Drug Targets.2009,(10):406-417.
[33]Gong W, Suzuki K, Russell M, et al. Function of the ING family of PHD proteins in cancer. Biochem Cell Biol.2005,37(5):1054-1065.
[34]Tallen UG, Truss M, Kunitz F.Down-regulation of the inhibitor of growth 1 (ING1) tumor suppressor sensitizes p53-deficient glioblastoma cells to cisplatin-induced cell death. Neurooncol.2008,86(1):23-30.
[35]Tsang FC,Po LS,Leung KM,et al.INGlb decreases cell proliferation through p53-dependentand-independent mechanislns. FEBS lett.2003,553(3):277-285.
[36]Jost CA, Marin MC, Kaelin WG Jr,et al.p73 is a human p53-related protein that can induce apoptosis.Nature,1997,389(6647):191-194.
[37]Irwin MS, Kaelim W C.P53 family update:p73 and p63 develop their own identities. Cell Growth Differ.2001,12(7):337-349.
[38]Moll UM, Slade N.p63 and p73:roles in development and tumor formation.Mol Cancer Res,2004,2(7):371-386..
[39]Tallen G, Kaiser I, Krabbe S, et al. No ING1 mutations in human brain tumours but reduced expression in high malignancy grades of astrocytoma. Cancer,2004,109(3):476-479.
[40]Vieyra D, Senger D L, Toyam T,et al. Altered subcellular localization and low f requency of mutations of ING1 in human brain tumors. Clin Cancer Res.2003,9 (16Pt1):5952-5961.
[41]Li XH, Noguchi A, Nishida T, et al.Cytoplasmic expression of p33ING1b is correlated with tumorigenesis and progression of head and neck squamous cell carcinoma.Histol Histopathol.2011,26(5):597-607.
[42]Campos El, Cheung KJ Jr, Murray A,et al. The novel tumour suppressor gene ING1 is overexpressed in human melanoma cell lines.Br J Dermatol.2002,146(4):574-580.
[43]Ohgi T,Masaki T,Nakai S,et al.Expression of p33 ING1in hepatocellular carcinoma relationships to tumour differentiation and cyclin E kinase activity. Scand J Gast roenterol, 2002,37(12):1440-1448.
[44]祝峙,林静,曲建慧,等.原发性肝细胞癌中p33ING1b与p53基因间协同功能的研究.中华医学杂志,2003,20(83)：1795-1799.
[45]Unoki M, Kumamoto K, Takenoshita S, Harris CC. Reviewing the current classification of inhibitor of growth family proteins. Cancer Science.2009,100(7):1173-1179.
[46]范大平,陈艳听,刘晓民.非小细胞肺癌中p33INGlb表达的临床意义.哈尔滨医科大学学报.2010,44(4)：352-357.
[47]G S Noumanl, J J Anderson 1, K M Woodl. Loss of nuclear expression of the p33INGlb inhibitor of growth protein in childhood acute lymphoblastic leukaemia. J Clin Pathol 2002,55:596-601.
[48]Helbing CC, Veillette C, Riabowol K, et al. Anovel candidate tumor suppressor,INGl,is involve in the regulation of apoptosis.Cancer Res,1997,57:1255-1258.
[49]Vieyra D, Toyama T, Hara Y,et al.ING1 isoforms differentially affect apoptosis in a cell age-dependent manner. Cancer Res.2002,62(15):4445.
[50]Shinoura N, Muramatsu Y, Nishimura M, et al. Adenovirus-mediated transfer of p33ING1 with p53 drastically augments apoptosis in gliomas. Cancer Res.1999,59(21):5521.
[51]Scott M,Boisvert FM, Vieyra D, et al. UV induces nucleolar translocation of ING1 through two distinct nucleolar targeting sequences. Nucleic Acids Res.2001,29(10):2052.
[52]Ohmori M, Nagia M,Tasaka T,etal. Decreased expression of p33ING1 mRNA in lymphoid malignancies. Hematol.1999,62(2):118.
[53]Niini T, Lahti L, Michelacci F, et al. Array comparative genomic hybridization reveals frequent alterations of Gl/S checkpoint genes in undifferentiated pleomorphic sarcoma of bone.Genes Chromosomes Cancer.2011,50(5):291-306.
[54]Tamannai M, Farhangi S, Truss M, et al. The inhibitor of growth-1 (ING1) is involved in trichostatin A-induced apoptosis and caspase 3 signaling in p53-deficient glioblastoma cells. Oncol Res.2010,18(10):469-480.
[55]Nouman GS, Anderson JJ, Lunec J, etal.The role of the tumour suppressor p33ING1b in human neoplasia. J Clin Pathol.2003,56(7):491-496.
[56]Nouman GS, Anderson JJ, Crosier S,et al. Downregulation of nuclear expression of the p33ING1b inhibitor of growth protein in invasive carcinoma of the breast. Clin Pathol. 2003,56(7):507-511.
[57]Li F, Li J, Sheng H,ET AL. Mutation of ING1 gene in laryngeal squamous cell carcinoma and its association with p33ING1b protein expression.Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi.2011,25(21):986-989.
[58]Linda JK, Carol P.P53:puzzle and paradime.Genes& Development,1996,(10):1054-1072.
[59]Janardhan S,Daxi S,Vincent JK,et al,Mutant p53 cooperates with ETS and selectively up-regulates human MDR1 not MRP1.J Biol Chem,2001,276(42):39359-39367.
[60]Wu Y, Mehew JW, Heckrnan CA, et al.Negative regulation of bcl-2 expression by p53 in hema topoietic cells.Oneogene,2001,20(2):240-251.
[61]Cheung K.JJR, Mitchell D, Lin P,et al.The tumor suppressor candidate p33ING1 mediates repair of UV-damaged DNA.Cancer Research.2001,61(13):4974-4977.
[62]Leung KM, Po LS, Tsang FC, et al. The candidate tumor suppressor INGlb can stabilize p53 by disrupting the regulation of p53 by MDM2. Cancer Res.2002,62(17):4890-4893.
[63]贺平,陈兴平.肿瘤抑制因子p33INGlb的研究进展.实用医学杂志.2008,24(21)：3784-3785.
[64]Gong W, Russell M, Suzuki K, et al.Subcellular targeting of p33ING1b by phosphorylation-dependent 14-3-3 binding regulates p21WAF1 expression. Mol Cell Biol. 2006,26(8):2947-2954.
[65]Davies C,Hogarth LA,Dietrich PA,et al.p53-independent epigenetic repression of the p21(WAF1) gene in T-cell acute lymphoblastic leukemia. J Biol Chem. 2011,286(43):37639-37650.
[66]Garkavtsev I, Boucher Y. An intact ING1-P53 pathway can potentiate the cytotoxic effects of taxol. Cancer Biol Ther.2005,4(1):48-49.
[67]Shimada H, Liu TL, Ochiai T, et al. Facilitation of adenoviral wild-type p53-induced apoptotic cell death by over expression of p33(ING1) in T. The human esophageal carcinoma cells. Oncogene.2002,21(8):1208-1216.
[68]Tyner JW, Jemal AM, Thayer M,et al.Leukemia.2011 Sep 30. Targeting survivin and p53 in pediatric acute lymphoblastic leukemia.
[69]Harris SL, Levine AJ.The p53 pathway:positiveand negative feedback loops.Oncogene. 2005,24(17):2899-2908.
[70]Garkavtsev I, Grigorian IA, Ossovskaya VS, et al.The candidate tumour suppressor p33ING1 cooperates with p53 in cell growth control.Nature.1998,391(6664):295.
[71].Berardi P, Russell M, El-Osta A, Riabowol K. Functional links between transcription, DNA repair and apoptosis. Cellular and Molecular Life Sciences.2004,61(17):2173-2180.
[72]Campos El, Chin MY, Kuo WH, Li G. Biological functions of the ING family tumor suppressors. Cellular and Molecular Life Sciences.2004,61(19-20):2597-2613.
[73]Liu JY,Wu BQ,Zheng J, et al.Effects of two varianta of ING1 expression on tumor cell growth regulation.Zhenghua Bing Li Xue Za Zhi.2003,32(1):48.
[74]Ronald P. C. Wong, Hanyang Lin, Shahram Khosravi,etal.Tumour suppressor INGlb maintains genomic stability upon replication stress. Nucleic Acids Res.2011 May; 39(9): 3632-3642.
[75]Zhu Z, Luo Z, Li Y, etal.Human inhibitor of growth 1 inhibits hepatoma cell growth and influences p53 stability in a variant-dependent manner. Hepatology.2009,49(2):504-12.
[76]Chen X, Du J, Zhu T.Pathol Biol (Paris). INGla and INGlb different expressed in sporadic hepatocellular carcinoma.2009,57(3):17-21.
[77]Shimada H, Liu TL,Ochiai T,et al.Facilitation of adenoviral wild-type p53-included apoptotic celll death by overexpression of p33IN lb in T.Tn human esophageal carcinoma cells.Oncogene,2002,21(8):1208-1216.
[78]庄静丽,徐建民,王宝珍等.急性白血.病p53蛋白表达的临床意义.中国临床医学,2005,12(3)：504-505.
[79]Schuler M, Green DR. Mechanisms of p53-dependent apoptosis.Biochem Soc Trans. 2001,29(6):684-688.
[80]朱晋军,廖威明,李佛保等.p33ING1b增强骨肉瘤细胞U20S对足叶乙甙的敏感性.癌症,2004,23(6)：640-644.
[81]Tallen G, Riabowol K, Wolff J E. Expression of p33ING1 mRNA and chemosensitivity in brain tumor cells. Anticancer Res,2003,23 (2B):1631-1635.
[82]Cheung KJ Jr, Li G.p33(ING1) enhances UVB-induced apoptosis in melanoma cells.Exp Cell Res.2002,279(2):291-298.
[83]Karpinich NO, Tafani M, Rothman RJ, et al.The course of etoposide-induced apoptosis from damage to DNA and p53 activation to mitochondrial release of cytochrome c.JBiol Chem.2002,277(19):16547-16552.
[84]Gunduz M, Gunduz E, Rivera RS,et al. The inhibitor of growth (ING) gene family: potential role in cancer therapy. Curr Cancer Drug Targets.2008,8(4):275-284.
[2]Ythier D, Larrieu D, Brambilla C,et al. The new tumor suppressor genes ING:Genomic structure and status in cancer. Int J Cancer.2008,123:1483-1490.
[3]Coles AH,Marfella CG,Imbalzano AN,et al. p37Inglb regulates B-cell proliferation and cooperates with p53 to suppress diffuse large B-cell lymphoma genesis. Cancer Res. 2008,68:8705-8714
[4]Garkavtsev I, Kazarov A,Riabowol K,et al.Suppression of the novel growth inhibitor p33ING1 promotes neoplastictransformation. Nat Genet.1996,14 (5):415-420.
[5]Baranova AV, Ivanov DV, Makeeva NV,et al. Genomic organization of a tumor growth inhibitor gene ING1. Mol Biol.2000,34:232-236.
[6]Gunduz M, Ouchida M, Fukushima K,et al. Genomic structure of the human ING1 gene and tumor-specific mutations detected in head and neck squamous cell carcinomas. Cancer Res.2000,60:3143-3146.
[7]Garkavtsev I.Suppression of the novel growth inhibitor p33 (ING1) promotes neoplastic transformation. Nat Genet.1999,23:373-73.
[8]Jager D,Stockert E,Scanlan MJ, et al. Cancer-testis antigens and ING1 tumor suppressor gene product are breast cancer antigens:characterization of tissue-specific ING1 transcripts and a homologue gene. Cancer Res.1999,59:6197-6204.
[9]Saito A,Furukawa T, Fukushige S, et al. p24/ING1-ALT1 and p47/ING1-ALT2, distinct alternative transcripts of p3ING1. Hum Genet.2000,45:177-181.
[10]Ha S, Park S, Yun CH, Choi Y. Characterization of nuclear localization signal in mouse ING1 homolog protein. Biochemical and Biophysical Research Communications.2002, 293(1):163-166.
[11]Nouman GS,Angus B,Lunec J, et al. Comparative assessment of ex2pression of the inhibitor of growth 1 gene (ING1) in normal and neoplastic tissues. Hybridoma.2002,21 (1):1-10.
[12]Tamannai M, Farhangi S, Truss M, et al. The inhibitor of growth 1 (ING1) is involved in trichostatin A-induced apoptosis and caspase 3 signaling in p53-deficient glioblastoma cells. Oncol Res.2010,18(10):469-480.
[13]Helbing CC, Veillette C, Riabowol K, et al. A novel candidate tumor suppressor, ING1, is involved in the regulation of apoptosis. Cancer Res.1997,57:1255-1258.
[14]Turovets NA, Agapova LS, Kopnin PB, et al. Inactivation of p33(ING1) tumor suppressor affects the function of the cell cycle "checkpoints" and stability of the genome. Genetika. 2000,36:305-12.
[15]Garkavtsev I.Suppression of the novel growth inhibitor P33ING1 promotes neoplastie transformation. Nat Genet.1999,23(3):373.
[16]Dan- Hua Shen,Kelvin Yuen- Kwong Chan,Ui-Soon Khoo,etal. Epigenetic and genetic alterations of p33ING1b in ovarian cancer.J Carcinogenesis.2005,26(4):855-863.
[17]Cheung K J Jr, Li G. The tumor suppressor ING1:structure and function.J Exp Cell Res.2001,268(1):1-6.
[18]Kuzmichev,Zhang Y,Erdjument-Bromage H,et al.Role of the Sin3- histone deacetylase complex in growth regulation by the candidate tumor suppress or p33INGI. Mol Cell Biol.2002,22(3):835-848.
[19]Scott M, Bonnefin P, Vieyra D, et al.UV- induced binding of INGI to PCNA regulates the in duetion of apoptosis.J Cell Sci.2001,114(ptl9):3455-3462.
[20]Lv Y, Purbey BK, Huang Y, Li S,et al.Adenovirus-mediated expression of p33(INGlb) induces apoptosis and inhibits proliferation in gastric adenocarcinoma cells in vitro.Gastric Cancer.2012, Jan 12.
[21]Shimada H,Liu TL,Ochiai T,et al. Faeiliation of adenoviral wild-type p53-induced apoptotie cell death by ovrexpresslon of p331NGI in T.Tnhuman esophageal earcinomaces Oneogene.2002,21:1208-1216.
[22]Oki E, Maehara Y,Tokumaga E,etal. Reduced expression of p33ING1b and the relationship with p53 expression in buman gastric cancer. Cancer Lett,1999,147:157-162.
[23]Toyama T,lwase H, Watson P,et al.Suppression of INGI expression in sporadic breast cancer Oncugene.1999,18:5187-5193.
[24]Oki E, Maehara Y, Tokunage E,etal. Reduced expression of p33 INGlb and the relationship with p53 expression in human gastric cancer. Carlcer Letters.1999,147-157.
[25]G S Noumanl, J J Andersonl, K M Wood,et al. Loss of nuclear expression of the p33INGlb inhibitor of growth protein in childhood acute lymphoblastic leukaemia. J Clin Pathol 2002,55:596-601.
[26]Campos El, Chin MY, Kuo WH. Biological functions of the ING family tumor suppressors. Cell Mol Life Sci.2004,61(19-20):2597-613.
[27]Coles AH, Jones SN. The ING gene family in the regulation of cell growth and tumorigenesis. Journal of Cellular Physiology.2009,18(1):45-57.
[28]Pena PV, Davrazou F, Shi X, et al. Molecular mechanism of histone H3K4me3 recognition by plant homeodomain of ING2. Nature.2006,442(7098):100-103.
[29]Nouman GS, Anderson JJ, Lunec J. The role of the tumour suppressor p33 INGlb in human neoplasia. Clin Pathol.2003,56:491-496.
[30]Ythier D, Larrieu D, Brambilla C, Brambilla E, Pedeux R. The new tumor suppressor genes ING:genomic structure and status in cancer. Cancer.2008,123:1483-1490.
[31]Garkavtsev I,Demetrick D,Riabowol K.Cellular localization and chromosome mapping of a novel candidate tumor suppressor gene (ING1).Cytogenet Cell Genet.1997,76(3-3):176-8.
[32]Nouman GS,Angus B,Lunec J,et al. Comparative assessment of expression of the inhibitor of growth 1 gene(ING1) in normal and neoplastic tissues. Hybridoma.2002,21(1):1-10.
[33]Ludwig S, Klitzsch A, Baniahmad A.The ING tumor suppressors in cellular senescence and chromatin. Cell Biosci.2011,1(1):25.
[34]Campos E1, Cheung KJ Jr, Murray A,et al. The novel tumour suppressor gene ING1 is overexpressed in human melanoma cell lines.Br J Dermatol.2002,146(4):574-580.
[35]贺平,陈兴平.肿瘤抑制因子p33 INGlb的研究进展.实用医学杂志.2008,24(21)：3784-3785.
[36]Goeman F, Thormeyer D, Abad M,et al. Growth inhibition by the tumor suppressor p33ING1 in immortalized and primary cells:Involvement of two silencing domains and effect of Ras. Mol Cell Biol.2005,25:422-431.
[37]Kuzmichev,Zhang Y,Erdjument-Bromage H,et al.Role of the Sin3-histone deacetylase complex in growth regulation by the candidate tumor suppress or P33(INGI). Mol Cell Biol.2002,22(3):835-848.
[38]Scott M, Bonnefin P, Vieyra D, et al.UV-induced binding of INGI to PCNA regulates the in duetion of apoptosis. Cell Sci,2001,114(19):3455-3462.
[39]李伟,周鹏,胡红梅.p33INGlb蛋白的结构及其基因分子生物学Science and Technology.2008,29(8):70-71.
[40]Menendez C, Abad M, Gomez-Cabello D, Moreno A, Palmero I. ING proteins in cellular senescence. Curr Drug Targets.2009,10:406-417.
[41]Abad M, Moreno A, Palacios A, Narita M, Blanco F, Moreno-Bueno G, Narita M, Palmero I. The tumor suppressor ING1 contributes to epigenetic control of cellular senescence. Aging Cell.2011,1:158-171.
[42]Schuler M, Green DR. Mechanisms of p53-dependent apoptosis.Biochem Soc Trans. 2001,29(6):684-688.
[43]朱晋军,廖威明,李佛保等.p33INGlb增强骨肉瘤细胞U20S对足叶乙甙的敏感性.癌症,2004,23(6)：640-644.
[44]Leung KM, Po LS, Tsang FC, et al.The candidate tumor suppressor INGlb can stabilize p53 by disrupting the regulation of p53 by MDM2.Cancer Res.2002,62(17):4890-4893.
[45]Tsang FC,Po LS,Leung KM,etal.INGlb decreases cell proliferation through p53-dependent and-independent mechanislns. FEBS Lett.2003,553(3):277-285.
[46]赵帅,贺修胜,吕文玲等.p33INGlb基因对SW480细胞生长增殖的影响.中国癌症杂志.2008,18(8)：578-582.
[47]Jost CA, Marin MC, Kaelin WG, et al.p73 is a human p53-related protein that can induce apoptosis.Nature.1997,389(6647):191-194.
[48]Irwin MS,Kaelim W C,P53 family update:p73 and p63 develop their own identities. Cell Growth Differ.2001,12(7):337-349.
[49]Moll UM. Slade N. p63 and p73:roles in development and tumor formation. Mol Cancer Res.2004,2(7):371-386.
[50]Ito K, Kinjo K, Nakazato T,et al. Expression and sequence analysis of p33INGlgene in myeloid leukemia. Hematology.2002,69:141-143.
[51]Nouman GS, Anderson JJ, Crosier S,et al. Down-regulation of nuclear expression of the p33ING1b inhibitor of growth protein in invasive carcinoma of the breast.J Clin Pathol.2003 Jul;56(7):507-511.
[1]Garkavtsev I, Riabowol K. Extension of the replicative life span of human diploid fibroblast by inhibition of the p33ING1 candidate tumor suppressor.Mol Cell Boil.1997,17:2014.
[2]Zeremski m, Horrigan SK, Grigorian IA,et al.Localizaton of the candidate tumor suppressor gene ING1 to human chromosome 13q34.Somat Cell Mol Genet.1997,23(3): 233.
[3]He GH, Helbing CC, Wagner MJ, Sensen CW, Riabowol K. Phylogenetic analysis of the ING family of PHD finger proteins. Mol Biol Evol.2005;22:104-116.
[4]Ludwig S, Klitzsch A, Baniahmad A. The ING tumor suppressors in cellular senescence and chromatin. Cell Biosic.2011 Jul 18;1(1):25.
[5]Coles AH, Jones SN. The ING gene family in the regulation of cell growth and tumorigenesis. J Cell Physiol.2009;218:45-57.
[6]Li X, Kikuchi K, Takano Y. ING Genes Work as Tumor Suppressor Genes in the Carcinogenesis of Head and Neck Squamous Cell Carcinoma. J Oncol.2011;2011:963614.
[7]Garkavtsev I, Demetrick D, Riabowol K.Cellular localization and chromosome mapping of a novel candidate tumor suppressor gene (INGl).Cytogenet Cell Genet.1997,76(3-3): 176-8.
[8]Gunduz M,Ouchida M,Fukushima K,et al.Genomic structure of the human ING1 gene and tumor-specific mutations detected in head and neck squamous cell carcinomas.Cancer Res.2000,60:3143.
[9]Garkavtsev I, Kazarov A,Riabowol K,et al.Suppression of the novel growth inhibitor p331NG1 promotes neoplastic transformation. J Nat Genet.1996,14 (5)).415-420.
[10]Cheung K J Jr, Li G. The tumor suppressor ING 1:structure and function.J Exp Cell Res. 2001,268(1):1-6.
[11]Gundun M, Ouchida M, Fukushima K, et al. Genomic structure of the human ING1 gene and tumor-specific mutations detected in head and neck squamous cell carcinomas.Cancer Res.2000,60:3143.
[12]Jager cer-testisD,Stockert E,Scanlan MJ,et al.Cancer-testis antigens and ING1 tumor suppressor hene product are breast cancer antigens:characterization of tissue-specific ING1 transcripts and a homologue gene.Cancer Res.1999,59:6197
[13]Jenuwein T,Allis CD.Translating the histone code. Science.2001,293(5532):1074-1080.
[14]He GH,Helbing CC,Wagner MJ,et al. Phylogenetic analysis of the ING family of PHD finger proteins. Mol BiolEvol.2005,22(1):104-116.
[15]Pena PV, Davrazou F, Shi X, et al. Molecular mechanism of histone H3K4me3 recognition by plant homeodomain of ING2. Nature.2006,442(7098):100-103.
[16]Turovets NA,Agapova LS,Kopnin PB,et al. Effect of inactivating the p33ING1 tumor suppressor on the function of cell cycle "checkpoints" and genome stability.Genetika.2000, 36(3):385.
[17]Goeman F, Thormeyer D, Abad M, et al. Growth inhibition by the tumor suppressor p33ING1 in immortalized and primary cells:Involvement of two silencing domains and effect of Ras. Mol Cell Biol.2005,25:422-431.
[18]Schwarze SR, DePrimo SE, Grabert LM, et al. Novel pathways associated with bypassing cellular senescence in human prostate epithelial cells. J Biol Chem.2002,17:14877-14883.
[19]Wong RP, Lin H, Khosravi S,et al. Tumour suppressor INGlb maintains genomic stability upon replication stress. Nucleic Acids Res.2011,39(9):3632-3642.
[20]Skowyra D, Zeremski M, Neznanov N, et al. Differential association of products of alternative transcripts of the candidate tumor suppressor ING1 with the mSin3/HDACl transcriptional compressor complex.Journal of Biological Chemistry. 2001,276(12):8734-8739.
[21]Vieyra D, Loewith R, Scott M, et al. Human ING1 proteins differentially regulate histone acetylation. Journal of Biological Chemistry.2002,277(33):29832-29839.
[22]Kuzmichev A, Zhang Y, Erdjument-Bromage H,et al. Role of the Sin3-histone deacetylase complex in growth regulation by the candidate tumor suppressor p33ING1.Molecular and Cellular Biology.2002,22(3):835-848.
[23]Scott M, Bonnefin P, Vieyra D, et al.UV-induced binding of INGI to PCNA regulates the in duetion of apoptosis.J Cell Sci,2001,114(19):3455-3462.
[24]李伟,周鹏,胡红梅.P33ING1b蛋白的结构及其基因分子生物学Science and Technology.2008,29(8):70-71.
[25]Leung KM, Po LS, T sang FC, et al. The candidate tumor suppressor INGlb can stabilize p53 by disrupting the regulation of p53 by MDM2. Cancer Res.2002,62(17):4890-4893.
[26]Li N, Li Q, Cao X,et al. The tumor suppressor p33INGlb upregulates p16INK4a expression and induces cellular senescence.FEBS Lett.2011,585(19):3106-3112.
[27]Abad M, Moreno A, Palacios A, et al. The tumor suppressor ING1 contributes to epigenetic control of cellular senescence. Aging Cell.2011,1:158-71.
[28]Vicencio JM, Galluzzi L, Tajeddine N, et al. Senescence, apoptosis or autophagy? When a damaged cell must decide its path-a mini-review. Gerontology.2008,54(2):92-99.
[29]Campisi J, Adda d, Fagagna F. Cellular senescence:when bad things happen to good cells. Nat Rev Mol Cell Biol.2007,8:729-740.
[30]Courtois-Cox S, Jones SL,Cichowski K. Many roads lead to oncogene-induced senescence Oncogene.2008,27:2801-9.
[31]Lara MF, Paramio JM, Mol Carcinog.The Rb family connects with the Tp53 family in skin carcinogenesis.2007,46(8):618-23.
[32]Menendez C, Abad M, Gomez-Cabello D, Moreno A, Palmero I. ING proteins in cellular senescence. Curr Drug Targets.2009,(10):406-417.
[33]Gong W, Suzuki K, Russell M, et al. Function of the ING family of PHD proteins in cancer. Biochem Cell Biol.2005,37(5):1054-1065.
[34]Tallen UG, Truss M, Kunitz F.Down-regulation of the inhibitor of growth 1 (ING1) tumor suppressor sensitizes p53-deficient glioblastoma cells to cisplatin-induced cell death. Neurooncol.2008,86(1):23-30.
[35]Tsang FC,Po LS,Leung KM,et al.INGlb decreases cell proliferation through p53-dependentand-independent mechanislns. FEBS lett.2003,553(3):277-285.
[36]Jost CA, Marin MC, Kaelin WG Jr,et al.p73 is a human p53-related protein that can induce apoptosis.Nature,1997,389(6647):191-194.
[37]Irwin MS, Kaelim W C.P53 family update:p73 and p63 develop their own identities. Cell Growth Differ.2001,12(7):337-349.
[38]Moll UM, Slade N.p63 and p73:roles in development and tumor formation.Mol Cancer Res,2004,2(7):371-386..
[39]Tallen G, Kaiser I, Krabbe S, et al. No ING1 mutations in human brain tumours but reduced expression in high malignancy grades of astrocytoma. Cancer,2004,109(3):476-479.
[40]Vieyra D, Senger D L, Toyam T,et al. Altered subcellular localization and low f requency of mutations of ING1 in human brain tumors. Clin Cancer Res.2003,9 (16Pt1):5952-5961.
[41]Li XH, Noguchi A, Nishida T, et al.Cytoplasmic expression of p33ING1b is correlated with tumorigenesis and progression of head and neck squamous cell carcinoma.Histol Histopathol.2011,26(5):597-607.
[42]Campos El, Cheung KJ Jr, Murray A,et al. The novel tumour suppressor gene ING1 is overexpressed in human melanoma cell lines.Br J Dermatol.2002,146(4):574-580.
[43]Ohgi T,Masaki T,Nakai S,et al.Expression of p33 ING1in hepatocellular carcinoma relationships to tumour differentiation and cyclin E kinase activity. Scand J Gast roenterol, 2002,37(12):1440-1448.
[44]祝峙,林静,曲建慧,等.原发性肝细胞癌中p33ING1b与p53基因间协同功能的研究.中华医学杂志,2003,20(83)：1795-1799.
[45]Unoki M, Kumamoto K, Takenoshita S, Harris CC. Reviewing the current classification of inhibitor of growth family proteins. Cancer Science.2009,100(7):1173-1179.
[46]范大平,陈艳听,刘晓民.非小细胞肺癌中p33INGlb表达的临床意义.哈尔滨医科大学学报.2010,44(4)：352-357.
[47]G S Noumanl, J J Anderson 1, K M Woodl. Loss of nuclear expression of the p33INGlb inhibitor of growth protein in childhood acute lymphoblastic leukaemia. J Clin Pathol 2002,55:596-601.
[48]Helbing CC, Veillette C, Riabowol K, et al. Anovel candidate tumor suppressor,INGl,is involve in the regulation of apoptosis.Cancer Res,1997,57:1255-1258.
[49]Vieyra D, Toyama T, Hara Y,et al.ING1 isoforms differentially affect apoptosis in a cell age-dependent manner. Cancer Res.2002,62(15):4445.
[50]Shinoura N, Muramatsu Y, Nishimura M, et al. Adenovirus-mediated transfer of p33ING1 with p53 drastically augments apoptosis in gliomas. Cancer Res.1999,59(21):5521.
[51]Scott M,Boisvert FM, Vieyra D, et al. UV induces nucleolar translocation of ING1 through two distinct nucleolar targeting sequences. Nucleic Acids Res.2001,29(10):2052.
[52]Ohmori M, Nagia M,Tasaka T,etal. Decreased expression of p33ING1 mRNA in lymphoid malignancies. Hematol.1999,62(2):118.
[53]Niini T, Lahti L, Michelacci F, et al. Array comparative genomic hybridization reveals frequent alterations of Gl/S checkpoint genes in undifferentiated pleomorphic sarcoma of bone.Genes Chromosomes Cancer.2011,50(5):291-306.
[54]Tamannai M, Farhangi S, Truss M, et al. The inhibitor of growth-1 (ING1) is involved in trichostatin A-induced apoptosis and caspase 3 signaling in p53-deficient glioblastoma cells. Oncol Res.2010,18(10):469-480.
[55]Nouman GS, Anderson JJ, Lunec J, etal.The role of the tumour suppressor p33ING1b in human neoplasia. J Clin Pathol.2003,56(7):491-496.
[56]Nouman GS, Anderson JJ, Crosier S,et al. Downregulation of nuclear expression of the p33ING1b inhibitor of growth protein in invasive carcinoma of the breast. Clin Pathol. 2003,56(7):507-511.
[57]Li F, Li J, Sheng H,ET AL. Mutation of ING1 gene in laryngeal squamous cell carcinoma and its association with p33ING1b protein expression.Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi.2011,25(21):986-989.
[58]Linda JK, Carol P.P53:puzzle and paradime.Genes& Development,1996,(10):1054-1072.
[59]Janardhan S,Daxi S,Vincent JK,et al,Mutant p53 cooperates with ETS and selectively up-regulates human MDR1 not MRP1.J Biol Chem,2001,276(42):39359-39367.
[60]Wu Y, Mehew JW, Heckrnan CA, et al.Negative regulation of bcl-2 expression by p53 in hema topoietic cells.Oneogene,2001,20(2):240-251.
[61]Cheung K.JJR, Mitchell D, Lin P,et al.The tumor suppressor candidate p33ING1 mediates repair of UV-damaged DNA.Cancer Research.2001,61(13):4974-4977.
[62]Leung KM, Po LS, Tsang FC, et al. The candidate tumor suppressor INGlb can stabilize p53 by disrupting the regulation of p53 by MDM2. Cancer Res.2002,62(17):4890-4893.
[63]贺平,陈兴平.肿瘤抑制因子p33INGlb的研究进展.实用医学杂志.2008,24(21)：3784-3785.
[64]Gong W, Russell M, Suzuki K, et al.Subcellular targeting of p33ING1b by phosphorylation-dependent 14-3-3 binding regulates p21WAF1 expression. Mol Cell Biol. 2006,26(8):2947-2954.
[65]Davies C,Hogarth LA,Dietrich PA,et al.p53-independent epigenetic repression of the p21(WAF1) gene in T-cell acute lymphoblastic leukemia. J Biol Chem. 2011,286(43):37639-37650.
[66]Garkavtsev I, Boucher Y. An intact ING1-P53 pathway can potentiate the cytotoxic effects of taxol. Cancer Biol Ther.2005,4(1):48-49.
[67]Shimada H, Liu TL, Ochiai T, et al. Facilitation of adenoviral wild-type p53-induced apoptotic cell death by over expression of p33(ING1) in T. The human esophageal carcinoma cells. Oncogene.2002,21(8):1208-1216.
[68]Tyner JW, Jemal AM, Thayer M,et al.Leukemia.2011 Sep 30. Targeting survivin and p53 in pediatric acute lymphoblastic leukemia.
[69]Harris SL, Levine AJ.The p53 pathway:positiveand negative feedback loops.Oncogene. 2005,24(17):2899-2908.
[70]Garkavtsev I, Grigorian IA, Ossovskaya VS, et al.The candidate tumour suppressor p33ING1 cooperates with p53 in cell growth control.Nature.1998,391(6664):295.
[71].Berardi P, Russell M, El-Osta A, Riabowol K. Functional links between transcription, DNA repair and apoptosis. Cellular and Molecular Life Sciences.2004,61(17):2173-2180.
[72]Campos El, Chin MY, Kuo WH, Li G. Biological functions of the ING family tumor suppressors. Cellular and Molecular Life Sciences.2004,61(19-20):2597-2613.
[73]Liu JY,Wu BQ,Zheng J, et al.Effects of two varianta of ING1 expression on tumor cell growth regulation.Zhenghua Bing Li Xue Za Zhi.2003,32(1):48.
[74]Ronald P. C. Wong, Hanyang Lin, Shahram Khosravi,etal.Tumour suppressor INGlb maintains genomic stability upon replication stress. Nucleic Acids Res.2011 May; 39(9): 3632-3642.
[75]Zhu Z, Luo Z, Li Y, etal.Human inhibitor of growth 1 inhibits hepatoma cell growth and influences p53 stability in a variant-dependent manner. Hepatology.2009,49(2):504-12.
[76]Chen X, Du J, Zhu T.Pathol Biol (Paris). INGla and INGlb different expressed in sporadic hepatocellular carcinoma.2009,57(3):17-21.
[77]Shimada H, Liu TL,Ochiai T,et al.Facilitation of adenoviral wild-type p53-included apoptotic celll death by overexpression of p33IN lb in T.Tn human esophageal carcinoma cells.Oncogene,2002,21(8):1208-1216.
[78]庄静丽,徐建民,王宝珍等.急性白血.病p53蛋白表达的临床意义.中国临床医学,2005,12(3)：504-505.
[79]Schuler M, Green DR. Mechanisms of p53-dependent apoptosis.Biochem Soc Trans. 2001,29(6):684-688.
[80]朱晋军,廖威明,李佛保等.p33ING1b增强骨肉瘤细胞U20S对足叶乙甙的敏感性.癌症,2004,23(6)：640-644.
[81]Tallen G, Riabowol K, Wolff J E. Expression of p33ING1 mRNA and chemosensitivity in brain tumor cells. Anticancer Res,2003,23 (2B):1631-1635.
[82]Cheung KJ Jr, Li G.p33(ING1) enhances UVB-induced apoptosis in melanoma cells.Exp Cell Res.2002,279(2):291-298.
[83]Karpinich NO, Tafani M, Rothman RJ, et al.The course of etoposide-induced apoptosis from damage to DNA and p53 activation to mitochondrial release of cytochrome c.JBiol Chem.2002,277(19):16547-16552.
[84]Gunduz M, Gunduz E, Rivera RS,et al. The inhibitor of growth (ING) gene family: potential role in cancer therapy. Curr Cancer Drug Targets.2008,8(4):275-284.